Affinage

CXXC5

CXXC-type zinc finger protein 5 · UniProt Q7LFL8

Length
322 aa
Mass
33.0 kDa
Annotated
2026-06-09
64 papers in source corpus 28 papers cited in narrative 29 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CXXC5 is a CXXC-type zinc-finger protein that binds unmethylated CpG dinucleotides and acts as a context-dependent integrator of developmental signaling, partitioning between a cytoplasmic role in Wnt regulation and a nuclear role in epigenetic and transcriptional control (PMID:19001364, PMID:32249801, PMID:39585161). In the cytoplasm it binds the PDZ domain of Dishevelled (Dvl) and serves as a negative-feedback inhibitor of canonical Wnt/β-catenin signaling, repressing targets such as Axin2; this interaction is structurally defined and pharmacologically tractable, as competitor peptides (PTD-DBM) and small molecules disrupting the CXXC5-Dvl interface reactivate Wnt signaling (PMID:19001364, PMID:27932247, PMID:26941261). Through this axis CXXC5 restrains osteoblast differentiation and bone mineral density, cutaneous wound healing, hair follicle regeneration, and growth-plate elongation, with loss-of-function or interface disruption consistently de-repressing these regenerative programs (PMID:25633194, PMID:26056233, PMID:28595998, PMID:30971423). In the nucleus, CXXC5 occupies CpG islands and anchors the 5-methylcytosine oxidases TET1 and TET2, and its loss causes genome-wide DNA hypomethylation; this anchoring stabilizes methylation at specific loci such as the Irf7 island required for the pDC interferon response (PMID:28416650, PMID:39585161). CXXC5 also nucleates transcriptional programs by binding chromatin together with pluripotency factors Nanog and Oct4 to drive Tet and neural gene expression in ES cells, and by directly binding and regulating defined promoters including Flk-1/VEGFR2, MBP, SMAD7, and MYCL1 (PMID:24136587, PMID:26462610, PMID:31433977, PMID:34621736, PMID:33241676). It modulates TGF-β/Smad signaling by competing with HDAC1 for Smad2/3 binding and partners with the CRL4B-NuRD complex to repress TSC1 and activate mTOR/PD-L1 in cancer (PMID:29036306, PMID:36539038). CXXC5 itself is a downstream target of BMP4, TGF-β, retinoid, E2-ERα, and HIF1A signaling, and its protein level is set by ubiquitin-proteasome–mediated degradation at defined lysine residues (PMID:27886276, PMID:29036306, PMID:38642782, PMID:40371716).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 2008 High

    Established CXXC5's first defined molecular role: a cytoplasmic Dvl-binding negative-feedback inhibitor of Wnt signaling induced downstream of BMP4.

    Evidence Co-IP, FRET, TOPflash reporter and RNAi in neural stem cells

    PMID:19001364

    Open questions at the time
    • Did not define the structural basis of the CXXC5-Dvl interaction
    • Nuclear functions not yet addressed
  2. 2009 Medium

    Identified CXXC5 (RINF) as a retinoid-inducible nuclear CXXC zinc-finger factor with a regulatory role in myelopoiesis, anchoring it to hematopoietic differentiation.

    Evidence Microarray profiling, shRNA knockdown and cell fractionation in APL/CD34+ cells

    PMID:19182210

    Open questions at the time
    • No direct DNA targets defined
    • Mechanism of transcriptional action unknown
  3. 2013 High

    Demonstrated CXXC5 is a sequence-specific transcriptional activator and a TGF-β/Smad-associated factor, expanding its role from Wnt inhibitor to direct gene regulator.

    Evidence In vitro DNA binding with mutagenesis on Flk-1 promoter, zebrafish/mouse loss-of-function (Flk-1); Co-IP/FRET with Smad3/4 and reporter assays (apoptosis)

    PMID:23906331 PMID:24136587

    Open questions at the time
    • Whether DNA binding requires cofactors not resolved
    • Smad-interaction stoichiometry and direct vs indirect effect unclear
  4. 2015 High

    Knockout mice converted the Wnt-inhibitor model into in vivo physiology, showing CXXC5 restrains bone formation, wound healing and myelination, and is a direct activator of myelin genes.

    Evidence CXXC5−/− bone (DEXA/micro-CT), skin wound and myelin (EM/electrophysiology) phenotyping, PTD-DBM competitor peptide, MBP promoter binding

    PMID:25633194 PMID:26056233 PMID:26462610

    Open questions at the time
    • Tissue-specific contribution of cytoplasmic vs nuclear pools not separated
    • How CXXC5 switches between repressor and activator unresolved
  5. 2016 High

    Defined the CXXC5-Dvl interface structurally and chemically, validating it as a druggable Wnt-activating target, and broadened CXXC5's epigenetic and regulatory repertoire.

    Evidence Dvl1 PDZ crystal structure + modeling; FP/NMR-validated small molecules with OVX rescue; SUV39H1 Co-IP and H3K9me at Cd40lg; ERE reporter/ChIP for E2-ERα regulation

    PMID:26896487 PMID:26941261 PMID:27886276 PMID:27932247

    Open questions at the time
    • Co-crystal of full CXXC5-Dvl complex not obtained
    • Generality of SUV39H1 recruitment beyond Cd40lg untested
  6. 2017 High

    Established CXXC5's nuclear epigenetic function as a TET2-anchoring protein that maintains CpG-island hypomethylation, and confirmed Wnt-inhibitory roles in hair follicles.

    Evidence CXXC5 KO mouse with Irf7 CGI bisulfite/methylation and TET2 ChIP plus IFN/viral challenge; CXXC5−/− hair regrowth and dermal papilla assays with PTD-DBM

    PMID:28416650 PMID:28595998

    Open questions at the time
    • Whether TET2 anchoring is genome-wide or locus-restricted not yet shown
    • Determinants of CXXC5 CGI selectivity unknown
  7. 2018 High

    Resolved how CXXC5 tunes TGF-β output, showing it is a TGF-β target that competes with HDAC1 for Smad2/3 to relieve HDAC1 inhibition.

    Evidence RNA-seq of TGF-β targets, CXXC5-HDAC1-Smad2/3 Co-IP and competition assay, growth/apoptosis readouts

    PMID:29036306

    Open questions at the time
    • Direct vs scaffold contribution to Smad transcription not separated
    • Single cell-context tested
  8. 2019 High

    Placed CXXC5 in pluripotency and TGF-β developmental networks, showing it co-occupies chromatin with Nanog/Oct4/TET1/TET2 and regulates Tet expression, and acts via Smad in cardiac development.

    Evidence ChIP-seq and Co-IP in mouse ESCs with KO differentiation assays; zebrafish ZF-CXXC/SMAD MH1 domain Co-IP, reporter, morpholino with hand2 rescue; Cxxc5−/− growth-plate phenotyping with interaction-screen inhibitor

    PMID:27077543 PMID:30971423 PMID:31433977

    Open questions at the time
    • Whether CXXC5 recruits or is recruited by pluripotency factors unclear
    • Direct vs indirect control of Tet loci not fully dissected
  9. 2020 Medium

    Confirmed direct unmethylated-CpG binding with recombinant protein while showing CXXC5 lacks intrinsic transcriptional activity, reframing it as a DNA-targeting scaffold; also linked CXXC5 to cell-cycle/myeloid differentiation.

    Evidence Recombinant CXXC5 CpG binding and reporter assays (negative for intrinsic activity); shRNA/overexpression in mouse LSK cells with cell-cycle/scRNA-seq

    PMID:32083332 PMID:32249801

    Open questions at the time
    • Cofactors conferring activation/repression in cells not enumerated here
    • Mechanism linking CXXC5 to cell-cycle regulators undefined
  10. 2021 Medium

    Mapped the CXXC5 interactome and added a direct epigenetic-repression target, showing CXXC domain-dependent binding to EMD/MAZ/MeCP2 and promoter-level repression of MYCL1 via CpG methylation maintenance.

    Evidence BioID/MS interactome with domain mapping and MeCP2 co-regulation; CXXC5 ChIP, bisulfite and histone-modification analysis on MYCL1 promoter with epistasis rescue in hepatic stellate cells

    PMID:34475492 PMID:34621736

    Open questions at the time
    • Functional consequence of most interactome partners untested
    • Generality of MeCP2 interplay beyond subset of genes unknown
  11. 2022 High

    Extended CXXC5's roles to erythropoiesis, ESC lineage choice, and cancer, defining direct promoter targets (SMAD7) and a repressive CRL4B-NuRD complex driving mTOR/PD-L1.

    Evidence RINF knockdown/SMAD7 ChIP and rescue in CD34+ cells with 5hmC profiling; Idax/Rinf ESC and embryo knockouts on Tet/neural/trophectoderm programs; CXXC5-CRL4B-NuRD Co-IP/ChIP-seq with xenografts; BMP/CXXC5 tumor-suppressor function in DIPG

    PMID:33241676 PMID:35390758 PMID:35915262 PMID:36539038

    Open questions at the time
    • How CXXC5 toggles between TET-anchoring and NuRD-repression complexes unresolved
    • Context determinants of tumor-suppressor vs oncogenic behavior unclear
  12. 2024 High

    Cemented CXXC5 as a genome-wide TET-anchoring methylation guardian and identified HIF1A as an upstream regulator driving proliferative cancer programs.

    Evidence CXXC5 KO with whole-genome bisulfite sequencing and TET1/TET2 ChIP co-localization; HIF1A ChIP on CXXC5 promoter with ZNF143/EGR1 downstream targets and xenografts

    PMID:38642782 PMID:39585161

    Open questions at the time
    • Why TET loss-of-anchoring causes net hypomethylation mechanistically not fully resolved
    • Direct vs indirect activation of ZNF143/EGR1 not separated
  13. 2025 High

    Defined how CXXC5 abundance is set, identifying specific ubiquitinated lysines that drive proteasomal degradation independent of cell-cycle phase.

    Evidence BioUbiquitination + sequential IP-MS, cycloheximide chase, proteasome inhibition and synchronization in MCF-7/HEK293FT

    PMID:40371716

    Open questions at the time
    • The responsible E3 ligase(s) not identified
    • Whether degradation is signal-regulated (e.g., by Wnt/TGF-β) untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved what molecular switch partitions CXXC5 between its cytoplasmic Dvl-bound Wnt-inhibitory pool and its nuclear CpG/TET-anchoring and complex-specific transcriptional pools, and how this dictates activator versus repressor outcomes.
  • No mechanism for cytoplasmic-nuclear partitioning defined
  • Determinants of complex selection (TET vs NuRD vs HDAC1/Smad) unknown
  • E3 ligase and signal-coupling of CXXC5 turnover unidentified

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003677 DNA binding 6 GO:0140110 transcription regulator activity 6 GO:0060090 molecular adaptor activity 4 GO:0098772 molecular function regulator activity 4
Localization
GO:0005694 chromosome 4 GO:0005634 nucleus 3 GO:0005829 cytosol 1
Pathway
R-HSA-74160 Gene expression (Transcription) 6 R-HSA-162582 Signal Transduction 5 R-HSA-4839726 Chromatin organization 5 R-HSA-1266738 Developmental Biology 4 R-HSA-392499 Metabolism of proteins 1
Complex memberships
CRL4B-NuRDCXXC5-TET1/TET2 (CpG island)Nanog-Oct4-Tet1-Tet2

Evidence

Reading pass · 29 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2008 CXXC5 co-localizes with Dishevelled (Dvl) in the cytoplasm and physically interacts with Dvl, as demonstrated by co-immunoprecipitation and FRET experiments. Overexpression of CXXC5 represses the canonical Wnt signaling target Axin2 and attenuates Wnt3a-mediated TOPflash reporter activity; RNAi knockdown of CXXC5 attenuates BMP4-mediated decrease in Axin2 levels, establishing CXXC5 as a BMP4-induced inhibitor of Wnt signaling in neural stem cells. Co-immunoprecipitation, FRET, TOPflash reporter assay, RNAi knockdown, Axin2 expression analysis The Journal of biological chemistry High 19001364
2009 CXXC5 (RINF) encodes a nuclear factor containing a CXXC-type zinc-finger motif that is induced by retinoids in acute promyelocytic leukemia cells; shRNA knockdown demonstrates a regulatory function in normal and tumoral myelopoiesis. Microarray expression profiling, shRNA knockdown, nuclear localization by cell fractionation Blood Medium 19182210
2013 CXXC5 is a transcriptional activator of the Flk-1 (VEGFR2) gene; in vitro DNA binding assay showed direct binding of CXXC5 to the Flk-1 promoter region, and mutation of the DNA-binding motif abolished transcriptional activity. BMP4 induces CXXC5 transcription which in turn induces Flk-1; CXXC5 knockdown suppressed BMP4-induced stress fiber formation and migration in HUVECs, and cxxc5 morpholino injection in zebrafish caused caudal vein plexus defects. In vitro DNA binding assay, promoter-reporter assay, site-directed mutagenesis, siRNA knockdown, morpholino zebrafish model, CXXC5−/− mouse Matrigel angiogenesis assay FASEB journal High 24136587
2013 CXXC5 interacts with Smad proteins (Smad3 and Smad4) as shown by co-localization and co-immunoprecipitation; CXXC5 facilitates Smad3 phosphorylation and Smad4 nuclear translocation, and co-expression of Smad with CXXC5 increases TNF-α reporter activity, linking CXXC5 to the extrinsic apoptosis pathway. FRET, co-immunoprecipitation, nuclear fractionation, caspase activity assay, TUNEL assay, transcription reporter assay, Western blot Current molecular medicine Medium 23906331
2015 CXXC5 negatively regulates osteoblast differentiation and bone formation via a Wnt-dependent interaction with Dvl. CXXC5-deficient mice exhibit elevated bone mineral density; a competitor peptide (PTD-DBM) blocking the CXXC5-Dvl interaction activates the Wnt/β-catenin pathway and accelerates ex vivo calvarial bone growth. CXXC5−/− mouse bone phenotyping (DEXA, micro-CT), co-immunoprecipitation of CXXC5-Dvl, competitor peptide functional assay, ex vivo calvarial culture Cell death and differentiation High 25633194
2015 CXXC5 acts as a negative feedback regulator of Wnt/β-catenin signaling in skin by interacting with Dvl. CXXC5−/− mice show accelerated cutaneous wound healing with enhanced β-catenin, collagen I, and keratin 14. PTD-DBM competitor peptide disrupts CXXC5-Dvl interaction; co-treatment with PTD-DBM and valproic acid synergistically accelerates wound healing. CXXC5−/− mouse wound healing model, overexpression/knockdown of CXXC5 in vitro, PTD-DBM competitor peptide, β-catenin/collagen measurements The Journal of experimental medicine High 26056233
2015 CXXC5 functions as a transcriptional activator of major myelin genes (including MBP) by directly binding the MBP promoter through its CXXC DNA-binding motif. CXXC5−/− mice show severely reduced myelin gene expression in corpus callosum, abnormal myelin structure, and reduced electrical conduction amplitudes. In vitro DNA binding assay (CXXC5 on MBP promoter), CXXC5−/− mouse myelin phenotyping (qPCR, electron microscopy, electrophysiology), neural stem cell differentiation assays Glia High 26462610
2016 Crystal structure of the mouse Dvl1 PDZ domain (1.76 Å resolution) was determined, and molecular modeling using NMR and X-ray data defined the Dvl1 PDZ domain binding pocket for the CXXC5 peptide, providing structural basis for the CXXC5-Dvl interaction. X-ray crystallography (1.76 Å resolution), NMR, molecular modeling Biochemical and biophysical research communications High 27932247
2016 Small-molecule inhibitors of the Dvl-CXXC5 interaction were identified and shown to activate the Wnt/β-catenin pathway and enhance osteoblast differentiation. NMR titration confirmed direct binding of compound KY-02061 to the Dvl PDZ domain. Oral administration of KY-02327 rescued bone loss in ovariectomized mice. Fluorescence polarization in vitro assay (Dvl-CXXC5 disruption), NMR titration, primary osteoblast differentiation assay, ex vivo calvaria culture, OVX mouse model EMBO molecular medicine High 26941261
2016 CXXC5 expression is induced by Wnt/β-catenin signaling and in turn directly binds the MBP promoter to activate myelin gene expression, positioning CXXC5 as part of a Wnt-driven transcriptional program in oligodendrocytes. Luciferase reporter assay, ChIP/DNA binding assay on MBP promoter, Wnt pathway modulation in neural stem cells Glia Medium 26462610
2016 CXXC5 induces H3K9 methylation at the Cd40lg promoter through association with the histone methyltransferase SUV39H1, thereby repressing CD40L expression in CD8+ cytotoxic T cells. ThPOK represses CXXC5 expression, thereby de-repressing CD40L. Retroviral Thpok transduction, CXXC5 transgene overexpression in T cells, chromatin modification analysis (H3K9me, H3K27me), co-immunoprecipitation of CXXC5 with SUV39H1 Journal of leukocyte biology Medium 26896487
2016 CXXC5 expression is regulated by E2-ERα through a direct estrogen response element (ERE) upstream of the CXXC5 translation start codon, establishing CXXC5 as an E2-ERα responsive gene. ERE-luciferase reporter assay, ERα ChIP, site-directed mutagenesis of ERE, qPCR/Western blot with E2 treatment Scientific reports Medium 27886276
2017 CXXC5 recruits DNA demethylase TET2 to maintain hypomethylation of CpG islands within IRF7 and other interferon pathway genes in plasmacytoid dendritic cells (pDCs). Genetic ablation of CXXC5 causes aberrant CpG methylation of the IRF7 gene locus, impairs IRF7 expression, and compromises TLR7/9- and virus-induced IFN response. This positions CXXC5 as an epigenetic regulator that anchors TET2 at specific CGIs. CXXC5 knockout mouse, bisulfite sequencing/methylation analysis of Irf7 CGI, TET2 recruitment assay (ChIP), IFN response assays, viral challenge model The Journal of experimental medicine High 28416650
2017 CXXC5 is a negative regulator of the Wnt/β-catenin pathway in hair follicles via interaction with Dvl. CXXC5 is upregulated in miniaturized follicles in human balding scalps. CXXC5 inhibits alkaline phosphatase activity and cell proliferation in human hair follicle dermal papilla cells; CXXC5−/− mice show accelerated hair regrowth; disrupting the CXXC5-Dvl interaction with PTD-DBM peptide activates Wnt/β-catenin and accelerates hair regrowth and wound-induced hair neogenesis. CXXC5−/− mouse hair regrowth model, wound-induced hair neogenesis model, PTD-DBM competitor peptide treatment, alkaline phosphatase activity assay, cell proliferation assay in dermal papilla cells The Journal of investigative dermatology High 28595998
2018 CXXC5 is a novel TGF-β target gene; knockdown of CXXC5 attenuates expression of a substantial portion of TGF-β target genes and ameliorates TGF-β-induced growth inhibition and apoptosis. CXXC5 associates with HDAC1 and competes with HDAC1 for interaction with Smad2/3, thereby abolishing the inhibitory effect of HDAC1 on TGF-β signaling. RNA-Seq identification of TGF-β target genes, CXXC5 knockdown, co-immunoprecipitation of CXXC5 with HDAC1 and Smad2/3, competition assay, cell growth/apoptosis assays Journal of molecular cell biology High 29036306
2019 Rinf (CXXC5) binds to the chromatin at promoters and enhancers of Tet1, Tet2, and pluripotency genes in mouse ESCs, where it forms a complex with Nanog, Oct4, Tet1, and Tet2, and facilitates their recruitment to regulatory regions. Rinf deficiency reduces expression of pluripotency factors and Tet enzymes and causes aberrant differentiation. ChIP-seq (Rinf occupancy), Co-immunoprecipitation (Rinf with Nanog, Oct4, Tet1, Tet2), Rinf KO mouse ESCs, RNA-seq, differentiation assays Cell reports High 31433977
2019 CXXC5 (RINF) mediates growth plate senescence via suppression of Wnt/β-catenin signaling through its interaction with Dvl. Cxxc5−/− mice show delayed growth plate senescence and tibial elongation. Indirubin analog KY19382, identified by an in vitro CXXC5-DVL interaction screening assay, disrupts this interaction and elongates tibial length. Cxxc5−/− mouse growth plate analysis, in vitro CXXC5-DVL interaction screening assay, tibial length measurement, growth plate histology Life science alliance Medium 30971423
2019 CXXC5 plays a zebrafish cardiac looping role via TGF-β signaling; zebrafish CXXC5 interacts with SMAD through its ZF-CXXC domain and SMAD MH1 domain. Overexpression of CXXC5 increases TGF-β luciferase reporter activity; cxxc5 morpholino knockdown causes cardiac looping defects rescued by hand2 mRNA co-injection. Co-immunoprecipitation (CXXC5-SMAD domain interaction), TGF-β luciferase reporter assay, zebrafish morpholino knockdown, mRNA rescue experiment International journal of cardiology Medium 27077543
2020 CXXC5 was verified by recombinant protein generation to directly bind unmethylated CpG dinucleotides. Despite this DNA-binding capacity, CXXC5 lacks intrinsic transcription activation/repression function but participates in E2-driven cellular proliferation by modulating expression of distinct and mutual genes regulated by E2. Recombinant CXXC5 protein production, in vitro unmethylated CpG binding assay, transcription activation/repression reporter assays (negative for intrinsic activity), gene expression profiling with CXXC5 overexpression/knockdown Scientific reports Medium 32249801
2020 Cxxc5 expression affects cell cycle and myeloid differentiation of mouse HSCs: knockdown reduces monocyte and increases granulocyte development; Cxxc5 knockdown increases S-phase fraction and proliferation, whereas overexpression decreases S-phase fraction; RNA-seq identified upregulation of cell cycle regulators after knockdown. shRNA knockdown and lentiviral overexpression in mouse LSK cells, flow cytometry cell cycle analysis, ex vivo myeloid differentiation, RNA-seq, single-cell RNA-seq Journal of leukocyte biology Medium 32083332
2021 CXXC5 binds the proximal MYCL1 promoter and represses MYCL1 transcription in quiescent hepatic stellate cells (HSCs). Loss of CXXC5 during HSC activation removes CpG methylation and acquires acetylated H3K9/H3K27 at the MYCL1 promoter, leading to MYCL1 transactivation and HSC activation. MYCL1 knockdown attenuates HSC activation; MYCL1 overexpression partially relieves CXXC5-mediated blockade. ChIP (CXXC5 on MYCL1 promoter), bisulfite sequencing, histone modification analysis, CXXC5 overexpression/knockout, RNA-seq, MYCL1 knockdown/overexpression functional assays Frontiers in cell and developmental biology High 34621736
2021 Proximity-dependent biotinylation (BioID) mapping identified CXXC5 interaction partners including DNA/chromatin modifiers, transcription factors/co-regulators, and RNA processors. CXXC5 interacts through its CXXC domain with EMD, MAZ, and MeCP2; interplay between CXXC5 and MeCP2 was critical for a subset of CXXC5 target gene expressions. BioID proximity biotinylation, sequential immunoprecipitation coupled to mass spectrometry, domain-interaction mapping, gene expression analysis of CXXC5/MeCP2 co-regulated genes Scientific reports Medium 34475492
2022 RINF (CXXC5) upregulates SMAD7 expression by direct binding to the SMAD7 promoter in immature erythroid cells, maintaining SMAD7 levels to fine-tune TGF-β sensitivity. RINF knockdown accelerates erythropoietin-driven maturation and reduces RBC numbers (~45%); ectopic SMAD7 expression rescues the RINF knockdown phenotype. RINF silencing also affects 5'-hydroxymethylation of erythroblasts, consistent with a Tet2-anchoring role. RINF shRNA knockdown in primary human CD34+ cells, promoter binding (ChIP), ectopic SMAD7 rescue experiment, 5-hydroxymethylcytosine profiling, erythroid differentiation assays Haematologica High 33241676
2022 Idax and Rinf (CXXC5) facilitate expression of Tet enzymes to promote neural and suppress trophectoderm programs during ESC differentiation. Individual or combined loss of Idax and Rinf in ESCs downregulates Tet genes (direct targets) and neural markers, and upregulates trophectoderm markers. DKO embryos have reduced NPC markers in forebrain and deregulated trophoblast markers in placenta. Single and double knockout ESCs, directed differentiation to NPCs and trophoblast-like cells, DKO mouse embryo analysis (NPC/trophoblast markers), qPCR/Western blot Stem cell research Medium 35390758
2022 CXXC5 interacts with the CRL4B and NuRD complexes and the CXXC5-CRL4B-NuRD complex mediates transcriptional repression of TSC1 and other genes, activating mTOR signaling and PD-L1 expression in breast cancer. ChIP-seq defined direct transcriptional targets of this complex. Co-immunoprecipitation (CXXC5 with CRL4B and NuRD components), ChIP-seq, loss-of-function (knockdown) and overexpression, in vitro proliferation and in vivo xenograft assays The Journal of biological chemistry Medium 36539038
2022 BMP signaling promotes exit of DIPG tumor cells from a stem-cell-like state to differentiation by epigenetically regulating CXXC5, which acts as a tumor suppressor and positive regulator of BMP signaling in H3.3K27M/ACVR1-WT DIPG. BMP ligand treatment, CXXC5 gain/loss-of-function in DIPG cells, epigenetic profiling, SMAD-dependent reporter assays, in vivo DIPG models Nature cancer Medium 35915262
2024 CXXC5 extensively co-localizes with TET1 and TET2 at CpG islands in mouse ES cells and interacts with 5-methylcytosine oxidases (TET proteins). CXXC5 knockout leads to substantial genome-wide DNA hypomethylation affecting all genomic compartments, consistent with a model in which CXXC5 anchors TET proteins at CpG islands and in its absence TET enzymes induce genome-scale demethylation. CXXC5 knockout (gene editing), whole-genome bisulfite sequencing, co-localization analysis of CXXC5 with TET1/TET2 (ChIP), RNA-seq Epigenomics High 39585161
2024 CXXC5 drives ovarian cancer cell proliferation via transcriptional activation of ZNF143 and EGR1 downstream transcription factors. CXXC5 expression is directly regulated by HIF1A (hypoxia). Loss of CXXC5 inactivates multiple inflammatory signaling pathways; in vitro and in vivo experiments confirmed ZNF143 and EGR1 as downstream transcriptional targets mediating CXXC5's proliferative effects. CXXC5 knockdown/overexpression, HIF1A ChIP (CXXC5 promoter), downstream target gene expression (ZNF143, EGR1), in vitro proliferation assays, in vivo xenograft Cellular signalling Medium 38642782
2025 CXXC5 protein is regulated post-translationally by ubiquitination and degraded via the ubiquitin-proteasome pathway. Specific ubiquitinated lysine residues of CXXC5 were identified by bioUbiquitination approach followed by sequential immunoprecipitation coupled to mass spectrometry; these lysine residues contribute to CXXC5 degradation in MCF-7 and HEK293FT cells. E2 augments CXXC5 transcription and synthesis in the G1 phase, but protein levels are primarily controlled by ubiquitination independently of cell cycle phase. BioUbiquitination approach (cellular biotinylation of ubiquitin), sequential immunoprecipitation coupled mass spectrometry, cell synchronization, cycloheximide chase, proteasome inhibitor treatment, Western blot Protein science High 40371716

Source papers

Stage 0 corpus · 64 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2018 NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression. Oncogene 91 29780166
2008 CXXC5 is a novel BMP4-regulated modulator of Wnt signaling in neural stem cells. The Journal of biological chemistry 91 19001364
2017 Epigenetic regulator CXXC5 recruits DNA demethylase Tet2 to regulate TLR7/9-elicited IFN response in pDCs. The Journal of experimental medicine 86 28416650
2015 CXXC5 is a negative-feedback regulator of the Wnt/β-catenin pathway involved in osteoblast differentiation. Cell death and differentiation 69 25633194
2015 The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing. The Journal of experimental medicine 56 26056233
2017 Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis. The Journal of investigative dermatology 50 28595998
2018 CXXC5: A novel regulator and coordinator of TGF-β, BMP and Wnt signaling. Journal of cellular and molecular medicine 48 30479059
2009 Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis. Blood 47 19182210
2018 CXXC5 suppresses hepatocellular carcinoma by promoting TGF-β-induced cell cycle arrest and apoptosis. Journal of molecular cell biology 41 29036306
2016 Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy. EMBO molecular medicine 41 26941261
2013 CXXC5 is a transcriptional activator of Flk-1 and mediates bone morphogenic protein-induced endothelial cell differentiation and vessel formation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 40 24136587
2016 ThPOK represses CXXC5, which induces methylation of histone H3 lysine 9 in Cd40lg promoter by association with SUV39H1: implications in repression of CD40L expression in CD8+ cytotoxic T cells. Journal of leukocyte biology 32 26896487
2017 KANK1 inhibits cell growth by inducing apoptosis through regulating CXXC5 in human malignant peripheral nerve sheath tumors. Scientific reports 30 28067315
2022 Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5. Nature cancer 28 35915262
2019 CXXC5 Mediates P. gingivalis-suppressed Cementoblast Functions Partially via MAPK Signaling Network. International journal of biological sciences 27 31360111
2015 CXXC5 plays a role as a transcription activator for myelin genes on oligodendrocyte differentiation. Glia 27 26462610
2019 CXXC5 mediates growth plate senescence and is a target for enhancement of longitudinal bone growth. Life science alliance 25 30971423
2016 Estradiol-Estrogen Receptor α Mediates the Expression of the CXXC5 Gene through the Estrogen Response Element-Dependent Signaling Pathway. Scientific reports 25 27886276
2021 Down-Regulation of CXXC5 De-Represses MYCL1 to Promote Hepatic Stellate Cell Activation. Frontiers in cell and developmental biology 24 34621736
2023 Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK. The Lancet. Oncology 23 37944542
2013 CXXC5 Associates with Smads to Mediate TNF-α Induced Apoptosis. Current molecular medicine 21 23906331
2014 CXXC5 regulates differentiation of C2C12 myoblasts into myocytes. Journal of muscle research and cell motility 20 25433557
2019 Rinf Regulates Pluripotency Network Genes and Tet Enzymes in Embryonic Stem Cells. Cell reports 19 31433977
2016 CXXC5 is required for cardiac looping relating to TGFβ signaling pathway in zebrafish. International journal of cardiology 19 27077543
2023 Inhibiting the cytosolic function of CXXC5 accelerates diabetic wound healing by enhancing angiogenesis and skin repair. Experimental & molecular medicine 18 37524876
2020 CXXC5 as an unmethylated CpG dinucleotide binding protein contributes to estrogen-mediated cellular proliferation. Scientific reports 18 32249801
2018 miR-32 promotes esophageal squamous cell carcinoma metastasis by targeting CXXC5. Journal of cellular biochemistry 18 30362164
2013 CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia. Oncotarget 18 23988457
2020 CXXC5 orchestrates Stat3/Erk/Akt signaling networks to modulate P. gingivalis-elicited autophagy in cementoblasts. Biochimica et biophysica acta. Molecular cell research 17 33285176
2018 Discovery of a small-molecule inhibitor of Dvl-CXXC5 interaction by computational approaches. Journal of computer-aided molecular design 17 29627878
2023 CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2. Cells 16 36831222
2022 The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer. Genome medicine 16 36258199
2023 The WID-EC test for the detection and risk prediction of endometrial cancer. International journal of cancer 14 36533702
2023 Inhibition of CXXC5 function rescues Alzheimer's disease phenotypes by restoring Wnt/β-catenin signaling pathway. Pharmacological research 14 37355147
2022 The WID-qEC test: Performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers. International journal of cancer 14 36056582
2022 Inhibition of CXXC5 function reverses obesity-related metabolic diseases. Clinical and translational medicine 13 35384342
2022 Metabolic improvement and liver regeneration by inhibiting CXXC5 function for non-alcoholic steatohepatitis treatment. Experimental & molecular medicine 12 36114279
2022 DNA methylation-based detection and prediction of cervical intraepithelial neoplasia grade 3 and invasive cervical cancer with the WID™-qCIN test. Clinical epigenetics 10 36414968
2022 Zinc-finger protein CXXC5 promotes breast carcinogenesis by regulating the TSC1/mTOR signaling pathway. The Journal of biological chemistry 10 36539038
2017 The Negative Regulator CXXC5: Making WNT Look a Little Less Dishevelled. The Journal of investigative dermatology 10 28967390
2016 Crystal structure of the PDZ domain of mouse Dishevelled 1 and its interaction with CXXC5. Biochemical and biophysical research communications 10 27932247
2020 Frontline Science: Cxxc5 expression alters cell cycle and myeloid differentiation of mouse hematopoietic stem and progenitor cells. Journal of leukocyte biology 9 32083332
2020 CXXC5 Attenuates Pulmonary Fibrosis in a Bleomycin-Induced Mouse Model and MLFs by Suppression of the CD40/CD40L Pathway. BioMed research international 8 32337277
2017 CXXC5 expression in prostate cancer: implications for cancer progression. International journal of experimental pathology 8 29027288
2024 CXXC5 drove inflammation and ovarian cancer proliferation via transcriptional activation of ZNF143 and EGR1. Cellular signalling 7 38642782
2021 A prelude to the proximity interaction mapping of CXXC5. Scientific reports 7 34475492
2024 High performance of the DNA methylation-based WID-qEC test for detecting uterine cancers independent of sampling modalities. International journal of cancer 5 38739012
2024 Performance of the WID-qEC test to detect uterine cancers in black women with abnormal uterine bleeding: A prospective observational cohort study in Ghana. International journal of cancer 5 39655721
2022 Blockade of CXXC5-dishevelled interaction inhibits adipogenic differentiation, obesity, and insulin resistance in mice. Scientific reports 5 36450849
2025 Signal integrator function of CXXC5 in Cancer. Cell communication and signaling : CCS 4 39806388
2024 CXXC5 mitigates P. gingivalis-inhibited cementogenesis by influencing mitochondrial biogenesis. Cell communication and signaling : CCS 4 38167023
2023 Histone Deacetylase 6 Inhibitor CKD-WID Suppressed Monosodium Urate-Induced Osteoclast Formation by Blocking Calcineurin-NFAT Pathway in RAW 264.7 Cells. Pharmaceuticals (Basel, Switzerland) 4 36986544
2022 The epigenetic regulator RINF (CXXC5) maintains SMAD7 expression in human immature erythroid cells and sustains red blood cells expansion. Haematologica 4 33241676
2022 Indirubin-3'-alkoxime derivatives for upregulation of Wnt signaling through dual inhibition of GSK-3β and the CXXC5-Dvl interaction. Bioorganic chemistry 4 35176556
2022 Idax and Rinf facilitate expression of Tet enzymes to promote neural and suppress trophectodermal programs during differentiation of embryonic stem cells. Stem cell research 4 35390758
2025 CXXC5 function blockade promotes diabetic wound healing through stimulating fibroblast and vascular endothelial cell activation. Cell communication and signaling : CCS 2 40001144
2024 CXXC5 stabilizes DNA methylation patterns in mouse embryonic stem cells. Epigenomics 2 39585161
2023 Undifferentially Expressed CXXC5 as a Transcriptionally Regulatory Biomarker of Breast Cancer. Advanced biology 2 37423953
2024 A novel study on CXXC5: unraveling its regulatory mechanisms in hematopoietic stem cell biology through proteomics and gene editing. Genes & genomics 1 39150611
2026 The cervico-vaginal DNA methylation WID-qEC test: An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer. International journal of cancer 0 41609407
2025 CXXC5 is a ubiquitinated protein and is degraded by the ubiquitin-proteasome pathway. Protein science : a publication of the Protein Society 0 40371716
2023 MiR-28-3p regulates high glucose-induced endothelial dysfunction by targeting CXXC5. Archives of medical science : AMS 0 40741256
2020 Author Correction: CXXC5 as an unmethylated CpG dinucleotide binding protein contributes to estrogen-mediated cellular proliferation. Scientific reports 0 32546710
1989 [Cutaneous lesion of adult T-cell lymphoma treated successfully with local hyperthermia in combination with intravenous administration of rINF-gamma]. Nihon Hifuka Gakkai zasshi. The Japanese journal of dermatology 0 2511361

Missed literature

Know a paper Affinage missed for CXXC5? Flag it for the maintainers and the community.

No submissions yet.